Nanovelos S.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2015-10-30
Share capital
1,010,208.20 PLN
Average employment (people)
2 (2025)
Activity description

Nanovelos is a biotechnology company specializing in the use of nanotechnology for oncological therapies. It develops polysaccharide-based drug carriers aimed at precise drug delivery for cancer treatment, specifically working on an effective drug using epirubicin (PolEpi) for ovarian cancer therapy. The company's technology aims to enhance treatment efficacy while minimizing adverse effects on patients.

Registered address
ul. Rakowiecka 36, 02-532 Warszawa, Poland
Phone
Electronic delivery address
AE:PL-17008-17306-VSFEJ-20

Financials

Revenue history (in k)

Financial insights

  • Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 – this may be an accounting template or the first year of the regime.
  • The statement flags a going concern risk. Zarząd wskazuje znaczącą niepewność dotyczącą kontynuacji działalności, związaną z ryzykiem projektów badawczo-rozwojowych i koniecznością pozyskiwania finansowania.

From the notes

Profit allocationLoss to be covered
Capital expenditure$68,106
Shareholders

Filing timeliness

1 of 6 financial statements was filed late (for 2023, 21 days late). All were audited by a statutory auditor.

  • 202514/07/2026
  • 202414/07/2025
  • 202305/08/2024
  • 202206/07/2023
  • 202130/06/2022
  • 202002/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 71%
Top 79%
City · Warszawa44,750 / 56,729
Top 79%
Voivodeship · Mazowieckie61,892 / 76,892
Top 80%
Country · Poland243,622 / 297,069
Top 82%

Results vs industry

Revenue
This companyUSD 24.84kMedianUSD 153.26kAverageUSD 4.77m
Net profit
This companyUSD -154.08kMedianUSD -293.45AverageUSD 306.55k
Operating costs
This companyUSD 174.65kMedianUSD 188.47kAverageUSD 4.59m
Assets
This companyUSD 30.17kMedianUSD 281.58kAverageUSD 8.35m

Offer

  • Research on drug carriers
  • Development of polysaccharide carriers
  • Drug delivery systems
  • Development of an anticancer drug
  • Oncology therapies

Website technology

Online shop
  • WooCommerce
Website
  • WordPress
Analytics and marketing
  • Google Analytics

Authorized Representatives

Tomasz Adam Ciach age 61 – Management Board Member
Przemysław Daniel Mazurek age 50 – President of the Management Board
Zbigniew Jerzy Posłajko age 56 – Attorney-in-fact (sole)
Piotr Paweł Mierzejewski age 62 – Management Board Member

Manner of representation

In the case of a one-person management board, the President of the Management Board is authorized to make declarations of will on behalf of the company and to represent the company. If a multi-member management board is appointed, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to perform legal acts and make declarations on behalf of the company.

Supervisory board

Robert Artur Dziubłowski age 63 – Supervisory Board Member
Stefan Marcin Bogusławski age 67 – Supervisory Board Member
Jerzy Krzysztof Garlicki age 61 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2013-04-25.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Jul 2, 2018Call to creditors

Public aid

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$3,930
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$3,841
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$3,751

European Funds

ProjectEU co-financing
Preclinical and clinical studies of innovative nanoformulations of anticancer drugs.
$2.5M

Competitors

Name
Medesto sp. z o.o.
WPD Pharmaceuticals S.A.
Orphinic Scientific S.A.
Onconick sp. z o.o.
Biolabic sp. z o.o.
Stenocoat sp. z o.o.
Cannamedai S.A.
Inventro S.A.
Oncotherics Poland S.A.
Cannabibs sp. z o.o.

Change history

DateEvent
2025-10-31Switch to PKD 2025
2025-01-24Share capital increase
2023-11-14Share capital increase
2023-06-12Share capital increase
2022-12-07Share capital increase

FAQ

Last updated: 2026-07-17